Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

BACKGROUND: Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium–iodide symporter and uptake of i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ho, Alan L., Grewal, Ravinder K., Leboeuf, Rebecca, Sherman, Eric J., Pfister, David G., Deandreis, Desiree, Pentlow, Keith S., Zanzonico, Pat B., Haque, Sofia, Gavane, Somali, Ghossein, Ronald A., Ricarte-Filho, Julio C., Domínguez, José M., Shen, Ronglai, Tuttle, R. Michael, Larson, Steve M., Fagin, James A.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3615415/
https://ncbi.nlm.nih.gov/pubmed/23406027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1209288
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars